FB   162.21 (+3.46%)
MSFT   159.11 (+6.29%)
AMZN   1,962.34 (+3.28%)
CGC   14.51 (-0.55%)
BABA   189.74 (+0.61%)
MU   45.15 (+3.84%)
GE   7.81 (+2.49%)
AMD   48.18 (+3.41%)
F   5.04 (-3.08%)
NFLX   373.23 (+4.51%)
GILD   74.90 (+2.81%)
DIS   96.87 (+0.49%)
FB   162.21 (+3.46%)
MSFT   159.11 (+6.29%)
AMZN   1,962.34 (+3.28%)
CGC   14.51 (-0.55%)
BABA   189.74 (+0.61%)
MU   45.15 (+3.84%)
GE   7.81 (+2.49%)
AMD   48.18 (+3.41%)
F   5.04 (-3.08%)
NFLX   373.23 (+4.51%)
GILD   74.90 (+2.81%)
DIS   96.87 (+0.49%)
FB   162.21 (+3.46%)
MSFT   159.11 (+6.29%)
AMZN   1,962.34 (+3.28%)
CGC   14.51 (-0.55%)
BABA   189.74 (+0.61%)
MU   45.15 (+3.84%)
GE   7.81 (+2.49%)
AMD   48.18 (+3.41%)
F   5.04 (-3.08%)
NFLX   373.23 (+4.51%)
GILD   74.90 (+2.81%)
DIS   96.87 (+0.49%)
FB   162.21 (+3.46%)
MSFT   159.11 (+6.29%)
AMZN   1,962.34 (+3.28%)
CGC   14.51 (-0.55%)
BABA   189.74 (+0.61%)
MU   45.15 (+3.84%)
GE   7.81 (+2.49%)
AMD   48.18 (+3.41%)
F   5.04 (-3.08%)
NFLX   373.23 (+4.51%)
GILD   74.90 (+2.81%)
DIS   96.87 (+0.49%)
Log in

NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

$2.07
-0.01 (-0.48 %)
(As of 03/30/2020 12:02 PM ET)
Today's Range
$2.01
Now: $2.07
$2.09
50-Day Range
$1.44
MA: $1.97
$2.51
52-Week Range
$1.15
Now: $2.07
$3.82
Volume5,034 shs
Average Volume354,993 shs
Market Capitalization$204.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Read More
CASI Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 million
Book Value$0.76 per share

Profitability

Net Income$-46,030,000.00

Miscellaneous

Employees124
Market Cap$204.97 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.


CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

How has CASI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CASI stock has increased by 27.0% and is now trading at $2.07. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for CASI Pharmaceuticals.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings results on Monday, March, 16th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $1.34 million during the quarter, compared to analysts' expectations of $1.16 million. View CASI Pharmaceuticals' earnings history.

What price target have analysts set for CASI?

1 analysts have issued twelve-month price objectives for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate CASI Pharmaceuticals' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

Media stories about CASI stock have been trending very positive on Monday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCASI Pharmaceuticals.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 54)
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
  • Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
  • Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include IDG Accel China Growth Fund III Associates L.P. (8.28%), Wellington Shields & Co. LLC (1.33%), State Street Corp (0.99%), Charles Schwab Investment Management Inc. (0.31%), California Public Employees Retirement System (0.13%) and Vident Investment Advisory LLC (0.07%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, and Bank of America Corp DE. View insider buying and selling activity for CASI Pharmaceuticals.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was acquired by a variety of institutional investors in the last quarter, including IDG Accel China Growth Fund III Associates L.P., Wellington Shields & Co. LLC, State Street Corp, Zebra Capital Management LLC, Charles Schwab Investment Management Inc., Barclays PLC, UBS Group AG, and Vident Investment Advisory LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.07.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $204.97 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe. View additional information about CASI Pharmaceuticals.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Holder of Record

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel